Plasma concentrations of interleukin-6, organ failure, vasopressor support, and successful coronary revascularization in predicting 30-day mortality of patients with cardiogenic shock complicating acute myocardial infarction

Critical Care Medicine

Volumn 34, Issue 8, 2006, Pages 2035-2042

  Geppert, Alexander ^b   Dorninger, Angela ^b   Delle Karth, Georg ^a   Zorn, Gerlinde ^a   Heinz, Gottfried ^a   Huber, Kurt ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b WILHELMINEN HOSPITAL   (Austria)

Author keywords

Acute myocardial infarction; Cardiogenic shock; Interleukin 6; Mortality; Renal failure

Indexed keywords

BIOLOGICAL MARKER; HYPERTENSIVE AGENT; INTERLEUKIN 6; LACTIC ACID; VASOCONSTRICTOR AGENT;

ACUTE HEART INFARCTION; ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; CARDIOGENIC SHOCK; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORRELATION ANALYSIS; DRUG MEGADOSE; FEMALE; HEART MUSCLE REVASCULARIZATION; HOSPITAL ADMISSION; HUMAN; INFLAMMATION; INTENSIVE CARE UNIT; LACTATE BLOOD LEVEL; LIVER FAILURE; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RESPIRATORY FAILURE; SENSITIVITY AND SPECIFICITY; SURVIVAL TIME; UNIVARIATE ANALYSIS; UNIVERSITY HOSPITAL; ARTIFICIAL VENTILATION; BLOOD; HEART INFARCTION; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; ROC CURVE;

AGED; BIOLOGICAL MARKERS; FEMALE; HUMANS; INTENSIVE CARE UNITS; INTERLEUKIN-6; KIDNEY FAILURE, ACUTE; LACTIC ACID; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RESPIRATION, ARTIFICIAL; RETROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; SHOCK, CARDIOGENIC; VASOCONSTRICTOR AGENTS;

EID: 33748124645     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000228919.33620.D9     Document Type: Article

References (35)

1. Hochman JS, Boland J, Sleeper LA, et al: Current spectrum of cardiogenic shock and effect of early revascularization on mortality. Results of an International Registry. SHOCK Registry Investigators. Circulation 1995; 91:873-881
2. Goldberg RJ, Samad NA, Yarzebski J, et al: Temporal trends in cardiogenic shock complicating acute myocardial infarction. N Engl J Med 1999; 340:1162-1168
3. Hochman JS, Sleeper LA, Webb JG, et al: Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med 1999; 341:625-634
4. Menon V, Slater JN, White HD, et al: Acute myocardial infarction complicated by systemic hypoperfusion without hypotension: Report of the SHOCK trial registry. Am J Med 2000; 108:374-380
5. Kohsaka S, Menon V, Lowe AM, et al: Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock. Arch Intern Med 2005; 165:1643-1650
6. Hochman JS: Cardiogenic shock complicating acute myocardial infarction: Expanding the paradigm. Circulation 2003; 107:2998-3002
7. Cotter G, Kaluski E, Milo O, et al: LINCS: L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock: A prospective randomized study. Eur Heart J 2003; 24:1287-1295
8. Cotter G, Kaluski E, Blatt A, et al: L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock. Circulation 2000; 101:1358-1361
9. Geppert A, Steiner A, Zorn G, et al: Multiorgan failure in patients with cardiogenic shock is associated with high plasma levels of interleukin-6. Crit Care Med 2002; 30:1987-1994
10. Casey LC, Balk RA, Bone RC: Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993; 119:771-778
11. Pinsky MR, Vincent JL, Deviere J, et al: Serum cytokine levels in human septic shock. Relation to multiple- system organ failure and mortality. Chest 1993; 103:565-575
12. Califf RM, Bengtson JR: Cardiogenic shock. N Engl J Med 1994; 330:1724-1730
13. Vincent JL, Moreno R, Takala J, et al: The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996; 22:707-710
14. Geppert A, Steiner A, Delle-Karth G, et al: Usefulness of procalcitonin for diagnosing complicating sepsis in patients with cardiogenic shock. Intensive Care Med 2003; 29:1384-1389
15. Patel MR, Mahaffey KW, Armstrong PW, et al: Prognostic usefulness of white blood cell count and temperature in acute myocardial infarction (from the CARDINAL Trial). Am J Cardiol 2005; 95:614-618
16. Deliargyris EN, Raymond RJ, Theoharides TC, et al: Sites of interleukin-6 release in patients with acute coronary syndromes and in patients with congestive heart failure. Am J Cardiol 2000; 86:913-918
17. Neumann FJ, Ott I, Gawaz M, et al: Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation 1995; 92:748-755
18. Lindmark E, Diderholm E, Wallentin L, et al: Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: Effects of an early invasive or noninvasive strategy. JAMA 2001; 286:2107-2113
19. Theroux P, Armstrong PW, Mahaffey KW, et al: Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: A substudy of the COMMA trial. Eur Heart J 2005; 26:1964-1970
20. Ikeda U, Ohkawa F, Seino Y, et al: Serum interleukin 6 levels become elevated in acute myocardial infarction. J Mol Cell Cardiol 1992; 24:579-584
21. Yamauchi-Takihara K, Ihara Y, Ogata A, et al: Hypoxic stress induces cardiac myocyte-derived interleukin-6. Circulation 1995; 91:1520-1524
22. Brunkhorst FM, Clark AL, Forycki ZF, et al: Pyrexia, procalcitonin, immune activation and survival in cardiogenic shock: The potential importance of bacterial translocation. Int J Cardiol 1999; 72:3-10
23. Liao J, Keiser JA, Scales WE, et al: Role of epinephrine in TNF and IL-6 production from isolated perfused rat liver. Am J Physiol 1995; 268:R896-R901
24. Finkel MS, Oddis CV, Jacob TD, et al: Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992; 257:387-389
25. Meldrum DR, Donnahoo KK: Role of TNF in mediating renal insufficiency following cardiac surgery: Evidence of a postbypass cardiorenal syndrome. J Surg Res 1999; 85:185-199
26. Koreny M, Delle-Karth G, Geppert A, et al: Prognosis of patients who develop acute renal failure during the first 24 hours of cardiogenic shock after myocardial infarction. Am J Med 2002; 112:115-119
27. Hasdai D, Holmes DR Jr, Califf RM, et al: Cardiogenic shock complicating acute myocardial infarction: Predictors of death. GUSTO Investigators. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries. Am Heart J 1999; 138:21-31
28. Tarantini G, Ramondo A, Isabella G, et al: Pressure response to vasopressors and mortality after direct angioplasty for cardiogenic shock. Int J Cardiol 2004; 94:197-202
29. Rao KM: Molecular mechanisms regulating iNOS expression in various cell types. J Toxicol Environ Health B Crit Rev 2000; 3:27-58
30. Wong SC, Sanborn T, Sleeper LA, et al: Angiographic findings and clinical correlates in patients with cardiogenic shock complicating acute myocardial infarction: A report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol 2000; 36:1077-1083
31. Chan AW, Chew DP, Bhatt DL, et al: Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction. Am J Cardiol 2002; 89:132-136
32. Antoniucci D, Valenti R, Migliorini A, et al: Abciximab therapy improves survival in patients with acute myocardial infarction complicated by early cardiogenic shock undergoing coronary artery stent implantation. Am J Cardiol 2002; 90:353-357
33. Casey LC: Role of cytokines in the pathogenesis of cardiopulmonary- induced multisystem organ failure. Ann Thorac Surg 1993; 56:S92-S96
34. Bone RC: Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: What we do and do not know about cytokine regulation. Crit Care Med 1996; 24:163-172
35. Panacek EA, Marshall JC, Albertson TE, et al: Efficacy and safety of the monoclonal antitumor necrosis factor antibody F(ab′)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 2004; 32:2173-2182